TABLE 1.
CLINICAL CHARACTERISTICS OF PATIENTS WITH ISOLATED MEDIASTINAL LYMPHADENOPATHY: THE REMEDY TRIAL
| Characteristic | EBUS-TBNA (n = 77) |
| Age, yr | |
| <30 | 15 (19%) |
| 30–49 | 34 (44%) |
| 50–69 | 16 (21%) |
| >69 | 12 (16%) |
| Median (range) | 42 (17–79) yr |
| Sex | |
| Male | 45 (58%) |
| Female | 32 (42%) |
| Ethnicity | |
| White | 25 (32%) |
| Asian | 29 (38%) |
| Black | 15 (19%) |
| Caribbean | 6 (8%) |
| Other | 2 (3%) |
| Symptom | |
| Cough | 27 (35%) |
| Dyspnea | 11 (14%) |
| Weight loss | 13 (17%) |
| Fevers/night sweats | 13 (17%) |
| Chest pain | 3 (4%) |
| Other | 2 (3%) |
| None | 8 (10%) |
| Final diagnosis | |
| Sarcoidosis stage 1 | 31 (40%) |
| Sarcoidosis stage 2 | 3 (4%) |
| Tuberculosis | 28 (36%) |
| Lymphoma | 3 (4%) |
| Extrathoracic malignancy | 4 (5%) |
| Lung cancer | 4 (5%) |
| Reactive lymphadenopathy | 4 (5%) |
Definition of abbreviations: EBUS-TBNA = endobronchial ultrasound–guided transbronchial needle aspiration; REMEDY = Clinical Trial of Endobronchial Ultrasound for the Diagnosis of Mediastinal Lymphadenopathy.